Dr. Lacey McNally is a Professor of Surgery, Stephenson Chair, a Standing Member of the Imaging Probes and Contrast Agents Study Section (NH), and Co-Leader of the Cancer Therapeutics Program at the Stephenson Cancer Center. Dr. McNally is a world-recognized leader in the development of contrast agents and Nano vehicles for improved detection, monitoring, and treatment of cancer and inflammation.
Dr. McNally conducted the first clinical trial using MSOT in the United States and is currently conducting three Phase 1 clinical trials.
Dr. McNally also serves as the Deputy Editor for Radiology: Imaging Cancer and Section Editor for Molecular Imaging and Biology. Her research focuses on the development of contrast agents and Nano-vehicles to improve the detection and treatment of cancer including breast, pancreas, ovarian, and colon, among other inflammatory diseases including colitis, Crohn’s, arthritis, and recently monitoring Duchenne muscular dystrophy and using MSOT.
Phone: (502) 744-6588
Location: 755 Research Parkway, Room 471 Oklahoma City, OK 73104